These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 14760417)

  • 1. EMSY, a BRCA-2 partner in crime.
    Livingston DM
    Nat Med; 2004 Feb; 10(2):127-8. PubMed ID: 14760417
    [No Abstract]   [Full Text] [Related]  

  • 2. Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY.
    Raouf A; Brown L; Vrcelj N; To K; Kwok W; Huntsman D; Eaves CJ
    J Natl Cancer Inst; 2005 Sep; 97(17):1302-6. PubMed ID: 16145051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel BRCA2-binding protein and breast and ovarian tumorigenesis.
    King MC
    N Engl J Med; 2004 Mar; 350(12):1252-3. PubMed ID: 15028830
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas.
    Madjd Z; Akbari ME; Zarnani AH; Khayamzadeh M; Kalantari E; Mojtabavi N
    Asian Pac J Cancer Prev; 2014; 15(4):1783-9. PubMed ID: 24641409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMSY promoted the growth and migration of ovarian cancer cells.
    Zhao X; Zhou Y; Nie M; Xian S; Chen H; Wen Y; Zhang L; Huang Y; Chen M; Wang S
    Tumour Biol; 2015 Apr; 36(4):3085-92. PubMed ID: 25510665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.
    Hughes-Davies L; Huntsman D; Ruas M; Fuks F; Bye J; Chin SF; Milner J; Brown LA; Hsu F; Gilks B; Nielsen T; Schulzer M; Chia S; Ragaz J; Cahn A; Linger L; Ozdag H; Cattaneo E; Jordanova ES; Schuuring E; Yu DS; Venkitaraman A; Ponder B; Doherty A; Aparicio S; Bentley D; Theillet C; Ponting CP; Caldas C; Kouzarides T
    Cell; 2003 Nov; 115(5):523-35. PubMed ID: 14651845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
    Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.
    Rodriguez C; Hughes-Davies L; Vallès H; Orsetti B; Cuny M; Ursule L; Kouzarides T; Theillet C
    Clin Cancer Res; 2004 Sep; 10(17):5785-91. PubMed ID: 15355907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY.
    Ezell SA; Polytarchou C; Hatziapostolou M; Guo A; Sanidas I; Bihani T; Comb MJ; Sourvinos G; Tsichlis PN
    Proc Natl Acad Sci U S A; 2012 Mar; 109(10):E613-21. PubMed ID: 22315412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis.
    Haber DA
    Cell; 2003 Nov; 115(5):507-8. PubMed ID: 14651841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akt1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the IFN response.
    Ezell SA; Tsichlis PN
    Transcription; 2012; 3(6):305-9. PubMed ID: 23117821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of BRCA1 and BRCA2 in the cellular response to ionizing radiation.
    Powell SN
    Radiat Res; 2005 Jun; 163(6):699-700. PubMed ID: 16044500
    [No Abstract]   [Full Text] [Related]  

  • 13. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1.
    Tian XX; Rai D; Li J; Zou C; Bai Y; Wazer D; Band V; Gao Q
    Cancer Res; 2005 Jun; 65(11):4747-53. PubMed ID: 15930293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.
    Jelinic P; Eccles LA; Tseng J; Cybulska P; Wielgos M; Powell SN; Levine DA
    Oncotarget; 2017 Feb; 8(8):13792-13804. PubMed ID: 28099152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.
    Mulrane L; Gallagher WM; O'Connor DP
    Breast Cancer Res; 2014 Nov; 16(6):467. PubMed ID: 25927669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
    Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
    Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
    [No Abstract]   [Full Text] [Related]  

  • 17. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
    Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
    Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMSY links breast cancer gene 2 to the 'Royal Family'.
    Yao J; Polyak K
    Breast Cancer Res; 2004; 6(5):201-3. PubMed ID: 15318925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of EMSY gene in sporadic ovarian cancer.
    Altinisik J; Karateke A; Coksuer H; Ulutin T; Buyru N
    Mol Biol Rep; 2011 Jan; 38(1):359-63. PubMed ID: 20349280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures.
    Hedenfalk IA
    J Natl Cancer Inst; 2002 Jul; 94(13):960-1. PubMed ID: 12096075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.